Myriad Genetics, Inc. (LON:0K3W)

Myriad Genetics Statistics

Total Valuation

Myriad Genetics has a market cap or net worth of GBP 497.10 million. The enterprise value is 556.28 million.

Market Cap	497.10M
Enterprise Value	556.28M

Important Dates

The next estimated earnings date is Tuesday, November 4, 2025.

Earnings Date	Nov 4, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	93.04M
Shares Outstanding	n/a
Shares Change (YoY)	+4.87%
Shares Change (QoQ)	+1.20%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	85.68M

Valuation Ratios

PE Ratio	n/a
Forward PE	193.45
PS Ratio	0.82
PB Ratio	1.75
P/TBV Ratio	4.09
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-1.93
EV / Sales	0.91
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-20.16

Financial Position

The company has a current ratio of 1.42, with a Debt / Equity ratio of 0.40.

Current Ratio	1.42
Quick Ratio	1.06
Debt / Equity	0.40
Debt / EBITDA	206.13
Debt / FCF	-4.09
Interest Coverage	-20.18

Financial Efficiency

Return on equity (ROE) is -70.03% and return on invested capital (ROIC) is -6.72%.

Return on Equity (ROE)	-70.03%
Return on Assets (ROA)	-5.44%
Return on Invested Capital (ROIC)	-6.72%
Return on Capital Employed (ROCE)	-16.07%
Revenue Per Employee	225,161
Profits Per Employee	-106,836
Employee Count	2,700
Asset Turnover	0.95
Inventory Turnover	8.99

Taxes

Income Tax	-18.39M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -70.81% in the last 52 weeks. The beta is 1.78, so Myriad Genetics's price volatility has been higher than the market average.

Beta (5Y)	1.78
52-Week Price Change	-70.81%
50-Day Moving Average	5.59
200-Day Moving Average	9.54
Relative Strength Index (RSI)	71.14
Average Volume (20 Days)	2,781

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	5.15

Income Statement

In the last 12 months, Myriad Genetics had revenue of GBP 607.93 million and -288.46 million in losses. Loss per share was -3.16.

Revenue	607.93M
Gross Profit	428.16M
Operating Income	-55.98M
Pretax Income	-306.85M
Net Income	-288.46M
EBITDA	-12.99M
EBIT	-55.98M
Loss Per Share	-3.16

Balance Sheet

The company has 54.30 million in cash and 112.84 million in debt, giving a net cash position of -58.54 million.

Cash & Cash Equivalents	54.30M
Total Debt	112.84M
Net Cash	-58.54M
Net Cash Per Share	n/a
Equity (Book Value)	283.27M
Book Value Per Share	3.04
Working Capital	61.60M

Cash Flow

In the last 12 months, operating cash flow was -16.50 million and capital expenditures -11.09 million, giving a free cash flow of -27.59 million.

Operating Cash Flow	-16.50M
Capital Expenditures	-11.09M
Free Cash Flow	-27.59M
FCF Per Share	n/a

Margins

Gross margin is 70.43%, with operating and profit margins of -9.21% and -47.45%.

Gross Margin	70.43%
Operating Margin	-9.21%
Pretax Margin	-50.47%
Profit Margin	-47.45%
EBITDA Margin	-2.14%
EBIT Margin	-9.21%
FCF Margin	n/a

Dividends & Yields

Myriad Genetics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-4.87%
Shareholder Yield	n/a
Earnings Yield	-58.03%
FCF Yield	-5.55%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Myriad Genetics has an Altman Z-Score of 1.78 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.78
Piotroski F-Score	3